Premium
Treatment of vibriosis in European sea bass larvae, Dicentrarchus labrax L., with oxolinic acid administered by bath or through medicated nauplii of Artemia franciscana (Kellogg): efficacy and residual kinetics
Author(s) -
Touraki M,
Niopas I,
Karagiannis V.
Publication year - 2012
Publication title -
journal of fish diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 85
eISSN - 1365-2761
pISSN - 0140-7775
DOI - 10.1111/j.1365-2761.2012.01387.x
Subject(s) - oxolinic acid , biology , sea bass , dicentrarchus , bass (fish) , shrimp , fishery , larva , zoology , antibiotics , microbiology and biotechnology , fish <actinopterygii> , ecology , nalidixic acid , antibiotic resistance
European sea bass larvae were challenged by bath with Listonella anguillarum strain 332A, 2.5 × 10 7 CFU mL −1 for 1 h. Fish either received no treatment or oral treatment with Artemia franciscana (Kellog) nauplii enriched with oxolinic acid, or bath treatments with oxolinic acid. Medication commenced 1 day following challenge and was performed on days 1, 3 and 5 post‐challenge at a dosage of 20 mg L −1 for 2 h for bath treatments, while two doses each of 750 nauplii per fish were administered daily for five consecutive days in oral treatments. Cumulative mortality reached 96% for the unmedicated challenged group, 32% in the group receiving bath treatments and 17% in the group receiving medicated nauplii. Pharmacokinetic parameters of oxolinic acid were calculated in sea bass larvae, for both treatments. Steady‐state concentrations of oxolinic acid of 48.0 and 75.2 μg g −1 were achieved for bath treatment and oral treatment, respectively, while the elimination half‐life was calculated to be 25.1 h for bath treatment and 21.7 h for oral treatment.